Down-regulated VEGF expression in the diabetic heart is normalized by an endothelin ETA receptor antagonist

Subrina Jesmin; Takashi Miyauchi; Katsutoshi Goto; Iwao Yamaguchi

doi:10.1016/j.ejphar.2006.04.041

Down-regulated VEGF expression in the diabetic heart is normalized by an endothelin ETA receptor antagonist

Eur J Pharmacol. 2006 Aug 7;542(1-3):184-5. doi: 10.1016/j.ejphar.2006.04.041.

Authors

Subrina Jesmin¹, Takashi Miyauchi, Katsutoshi Goto, Iwao Yamaguchi

Affiliation

¹ Cardiovascular Division, Department of Internal Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.

PMID: 16906650
DOI: 10.1016/j.ejphar.2006.04.041

Abstract

Recently, down-regulation of vascular endothelial growth factor (VEGF) in the heart was suggested as a potential molecular explanation for the increased risk of cardiovascular morbidity and mortality in patients with diabetes. Increased endothelin-1 production is reported in diabetes. Here, we report that down-regulated VEGF expression in the diabetic rat heart is normalized by an endothelin ETA receptor antagonist, suggesting that endothelin antagonism may be a novel therapeutic strategy for diabetic heart.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Analysis of Variance
Animals
Diabetes Mellitus, Experimental / genetics*
Diabetes Mellitus, Experimental / pathology
Diabetes Mellitus, Experimental / prevention & control
Down-Regulation / drug effects
Down-Regulation / genetics
Endothelin A Receptor Antagonists
Gene Expression / drug effects*
Heart Ventricles / drug effects*
Heart Ventricles / metabolism
Heart Ventricles / physiopathology
Male
Pyrimidines / pharmacology*
RNA, Messenger / genetics
RNA, Messenger / metabolism
Rats
Rats, Sprague-Dawley
Sulfonamides / pharmacology*
Vascular Endothelial Growth Factor A / genetics*

Substances

Endothelin A Receptor Antagonists
Pyrimidines
RNA, Messenger
Sulfonamides
T 0201
Vascular Endothelial Growth Factor A